Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI.
Vallejo-Vaz AJ, Bray S, Villa G, Brandts J, Kiru G, Murphy J, Banach M, De Servi S, Gaita D, Gouni-Berthold I, Kees Hovingh G, Jozwiak JJ, Jukema JW, Gabor Kiss R, Kownator S, Iversen HK, Maher V, Masana L, Parkhomenko A, Peeters A, Clifford P, Raslova K, Siostrzonek P, Romeo S, Tousoulis D, Vlachopoulos C, Vrablik M, Catapano AL, Poulter NR, Ray KK; DA VINCI Study Investigators.
Vallejo-Vaz AJ, et al. Among authors: kiru g.
Cardiovasc Drugs Ther. 2023 Oct;37(5):941-953. doi: 10.1007/s10557-022-07343-x. Epub 2022 May 14.
Cardiovasc Drugs Ther. 2023.
PMID: 35567726
Free PMC article.